The scientist’s investigation covers issues in Internal medicine, Lymphoma, Surgery, Oncology and Chemotherapy. In her study, Prospective cohort study and Pulmonary function testing is inextricably linked to Gastroenterology, which falls within the broad field of Internal medicine. The concepts of her Lymphoma study are interwoven with issues in Clinical trial, Incidence and Tositumomab.
Her work focuses on many connections between Surgery and other disciplines, such as Pediatrics, that overlap with her field of interest in Menopause, Pharmacotherapy, Referral and Cohort. Her Oncology research incorporates elements of Stanford V, Survival rate, Follicular lymphoma, Survival analysis and Aggressive lymphoma. Her Chemotherapy research incorporates themes from Platelet, Radiation therapy and Granulocyte.
Her primary areas of study are Internal medicine, Oncology, Lymphoma, Surgery and Chemotherapy. Her work in Internal medicine tackles topics such as Gastroenterology which are related to areas like Neutropenia. Her Oncology study also includes
Her work is dedicated to discovering how Lymphoma, Nuclear medicine are connected with Radioimmunotherapy and other disciplines. Sandra J. Horning has researched Rituximab in several fields, including Clinical endpoint, Follicular lymphoma, Diffuse large B-cell lymphoma and Phases of clinical research. Her Stanford V study integrates concerns from other disciplines, such as Survival analysis and BEACOPP.
Internal medicine, Oncology, Rituximab, Vincristine and Lymphoma are her primary areas of study. Her Internal medicine research includes elements of Gastroenterology and Surgery. Her Oncology study incorporates themes from CHOP, Chemotherapy, Randomized controlled trial, Immunology and Retrospective cohort study.
Sandra J. Horning combines subjects such as Phases of clinical research, Regimen, Clinical endpoint, Follicular lymphoma and Dosing with her study of Rituximab. Her Vincristine study combines topics in areas such as Survival rate, Mantle cell lymphoma, Nuclear medicine and Prednisone. Her research in Lymphoma intersects with topics in Methylation, Monoclonal, Virology, Confidence interval and Lytic cycle.
Her scientific interests lie mostly in Internal medicine, Oncology, Dacarbazine, Rituximab and Vincristine. Sandra J. Horning focuses mostly in the field of Internal medicine, narrowing it down to matters related to Surgery and, in some cases, Hazard ratio. Her work carried out in the field of Oncology brings together such families of science as Young adult, Clinical endpoint, Retrospective cohort study and Survival rate.
Her Rituximab research integrates issues from Follicular lymphoma and Phases of clinical research. Her Vincristine study which covers Prednisone that intersects with Procarbazine. The various areas that Sandra J. Horning examines in her Bleomycin study include Gastroenterology and Radiation therapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A predictive model for aggressive non-Hodgkin's lymphoma
M. A. Shipp;D. P. Harrington;J. R. Anderson;J. O. Armitage.
The New England Journal of Medicine (1993)
Revised response criteria for malignant lymphoma
Bruce D. Cheson;Beate Pfistner;Malik E. Juweid;Randy D. Gascoyne.
Journal of Clinical Oncology (2007)
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
B D Cheson;S J Horning;B Coiffier;M A Shipp.
Journal of Clinical Oncology (1999)
Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
Thomas M. Habermann;Edie A. Weller;Vicki A. Morrison;Randy D. Gascoyne.
Journal of Clinical Oncology (2006)
The natural history of initially untreated low-grade non-Hodgkin's lymphomas.
Sandra J. Horning;Saul A. Rosenberg.
The New England Journal of Medicine (1984)
Natural history of and therapy for the indolent non-Hodgkin's lymphomas.
Seminars in Oncology (1993)
Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients.
Jordan U. Gutterman;Seymour Fine;Jorge Quesada;Sandra J. Horning.
Annals of Internal Medicine (1982)
Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis.
L W Kwak;J Halpern;R A Olshen;S J Horning.
Journal of Clinical Oncology (1990)
ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma
Ralph M. Meyer;Mary K. Gospodarowicz;Joseph M. Connors;Robert G. Pearcey.
The New England Journal of Medicine (2012)
High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices.
Sandra J. Horning;Nelson J. Chao;Robert S. Negrin;Richard T. Hoppe.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: